Skip to main content
Erschienen in: Critical Care 5/2010

01.10.2010 | Commentary

Waking up the gut in critically ill patients

verfasst von: Juris J Meier

Erschienen in: Critical Care | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Multiorgan failure frequently develops in critically ill patients. While therapeutic efforts in such patients are often focused on the lungs, on the cardiovascular system as well as on the kidneys, it is important to also consider the functional alterations in gut motility and hormone secretion. Given the central regulatory functions of many gut hormones, such as glucagon-like peptide 1, glucagon-like peptide 2, ghrelin and others, exogenous supplementation of some of these factors may be beneficial under conditions of critical illness. From a pragmatic point of view, the most feasible way towards a restoration of gut hormone secretion in critically ill patients is to provide enteral nutritional supply as soon as possible.
Literatur
1.
Zurück zum Zitat Deane A, Chapman MJ, Fraser RJL, Horowitz M: Bench-to-bedside review: The gut as an endocrine organ in the critically ill. Crit Care 2010,14(5):228. 10.1186/cc9039PubMedCentralCrossRefPubMed Deane A, Chapman MJ, Fraser RJL, Horowitz M: Bench-to-bedside review: The gut as an endocrine organ in the critically ill. Crit Care 2010,14(5):228. 10.1186/cc9039PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Kang W, Kudsk KA: Is there evidence that the gut contributes to mucosal immunity in humans? JPEN J Parenter Enteral Nutr 2007, 31: 246-258. 10.1177/0148607107031003246CrossRefPubMed Kang W, Kudsk KA: Is there evidence that the gut contributes to mucosal immunity in humans? JPEN J Parenter Enteral Nutr 2007, 31: 246-258. 10.1177/0148607107031003246CrossRefPubMed
4.
Zurück zum Zitat Meier JJ, Nauck MA: Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005, 21: 91-117. 10.1002/dmrr.538CrossRefPubMed Meier JJ, Nauck MA: Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005, 21: 91-117. 10.1002/dmrr.538CrossRefPubMed
5.
Zurück zum Zitat Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91: 301-307. 10.1172/JCI116186PubMedCentralCrossRefPubMed Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91: 301-307. 10.1172/JCI116186PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Nauck MA: Is glucagon-like peptide 1 an incretin hormone? Diabetologia 1999, 42: 373-379. 10.1007/s001250051165CrossRefPubMed Nauck MA: Is glucagon-like peptide 1 an incretin hormone? Diabetologia 1999, 42: 373-379. 10.1007/s001250051165CrossRefPubMed
7.
Zurück zum Zitat Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002, 440: 269-279. 10.1016/S0014-2999(02)01434-6CrossRefPubMed Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002, 440: 269-279. 10.1016/S0014-2999(02)01434-6CrossRefPubMed
8.
Zurück zum Zitat Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128: 135-148. 10.1016/j.regpep.2004.07.014CrossRefPubMed Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128: 135-148. 10.1016/j.regpep.2004.07.014CrossRefPubMed
9.
Zurück zum Zitat Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M: Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005, 289: E504-E507. 10.1152/ajpendo.00099.2005CrossRefPubMed Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M: Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005, 289: E504-E507. 10.1152/ajpendo.00099.2005CrossRefPubMed
10.
Zurück zum Zitat Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W: Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118: 89-97. 10.1016/j.regpep.2003.11.003CrossRefPubMed Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W: Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118: 89-97. 10.1016/j.regpep.2003.11.003CrossRefPubMed
11.
Zurück zum Zitat Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109: 962-965. 10.1161/01.CIR.0000120505.91348.58CrossRefPubMed Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109: 962-965. 10.1161/01.CIR.0000120505.91348.58CrossRefPubMed
12.
Zurück zum Zitat Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36: 741-744. 10.1007/BF00401145CrossRefPubMed Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36: 741-744. 10.1007/BF00401145CrossRefPubMed
13.
Zurück zum Zitat Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B: Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32: 848-851. 10.1097/01.CCM.0000114811.60629.B5CrossRefPubMed Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B: Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32: 848-851. 10.1097/01.CCM.0000114811.60629.B5CrossRefPubMed
14.
Zurück zum Zitat Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B: Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102: 646-647. 10.1016/j.amjcard.2008.06.029CrossRefPubMed Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B: Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102: 646-647. 10.1016/j.amjcard.2008.06.029CrossRefPubMed
15.
Zurück zum Zitat Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M: The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009, 13: R67. 10.1186/cc7874PubMedCentralCrossRefPubMed Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M: The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009, 13: R67. 10.1186/cc7874PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Schmidt WE: The intestine, an endocrine organ. Digestion 1997,58(Suppl 1):56-58. 10.1159/000201528CrossRefPubMed Schmidt WE: The intestine, an endocrine organ. Digestion 1997,58(Suppl 1):56-58. 10.1159/000201528CrossRefPubMed
17.
Zurück zum Zitat Mesotten D, Vanhorebeek I, Van den Berghe G: The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008, 4: 496-505. 10.1038/ncpendmet0921CrossRefPubMed Mesotten D, Vanhorebeek I, Van den Berghe G: The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008, 4: 496-505. 10.1038/ncpendmet0921CrossRefPubMed
Metadaten
Titel
Waking up the gut in critically ill patients
verfasst von
Juris J Meier
Publikationsdatum
01.10.2010
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 5/2010
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9079

Weitere Artikel der Ausgabe 5/2010

Critical Care 5/2010 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.